Siyi Gu

This study uses APEX2 proximity labeling and mass spectrometry to uncover ligand-dependent CCR5 trafficking mechanisms, revealing distinct internalization and degradation pathways.

This paper introduces cataLYTACs, a new therapeutic modality that efficiently and durably degrades circulating proteins like IgE in vitro and in vivo, outperforming traditional inhibitors.

This study identifies molecular determinants of CCR2 and CCR5 antagonist interactions using docking and AI screening, revealing structural principles and selectivity mechanisms.